US Market Is Still Waiting for Biosimilars to Produce Meaningful Price Reductions
March 14th 2019When the FDA approved its first biosimilar drug in 2015—filgrastim-sndz, for compromised white blood cell count—there was talk of the benefits of competition in the pharma industry; increased access to medications for patients; and, of course, the all-around savings. Four years later, those benefits haven’t been fully realized,
Read More
Heightened Risk for Natural Disasters Necessitates Advance Preparation in Oncology Community
February 5th 2019With hugely destructive storms now almost routine—3 of the 5 costliest hurricanes on record occurred in 2017—the secret to practice readiness is constant review and analysis.
Read More